Physician profile
Michael E Johnson
NPI 1760426852
$2,474.69
in general payments reported to CMS, 2019-2025
33 companies · $287 in 2025
The $287 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $383 · 2020: $216 · 2021: $507 · 2022: $485 · 2023: $517 · 2024: $79.67 · 2025: $287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $884.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $883.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $770.24 | 2021-2025 | |
| Glaxosmithkline, LLC. | $213.09 | 2019-2021 | |
| Amgen INC. | $163.90 | 2019-2021 | |
| Novo Nordisk INC | $152.37 | 2020-2024 | Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $142.81 | 2021-2025 | Rexulti |
| Allergan, INC. | $120.15 | 2019-2020 | |
| Lilly USA, LLC | $77.98 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $68.38 | 2022-2023 | |
| Pfizer INC. | $63.04 | 2021-2025 | |
| Zimmer Biomet Holdings, INC. | $59.15 | 2021 | |
| Janssen Pharmaceuticals, INC | $53.61 | 2019-2020 | |
| Paragon 28, INC. | $47.45 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.48 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.07 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $44.80 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $35.75 | 2023 | Myrbetriq, Veozah |
| Abiomed | $34.71 | 2025 | |
| Merck Sharp & Dohme LLC | $34.37 | 2020-2025 | Gardasil 9, Vaxneuvance, Rotateq |
| Biohaven Pharmaceutical Holding Company LTD. | $31.49 | 2022 | |
| Nestle Healthcare Nutrition INC. | $28.98 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $24.88 | 2021-2023 | Seglentis, Livalo |
| Arbor Pharmaceuticals, INC. | $24.07 | 2021 | |
| Sanofi-Aventis U.S. LLC | $24.06 | 2022 | |
| Gilead Sciences, INC. | $23.74 | 2025 | Epclusa |
| Organon LLC | $22.00 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $18.29 | 2025 | Austedo Xr |
| Exact Sciences Corporation | $17.34 | 2023 | Cologuard Collection Kit |
| Bausch Health US, LLC | $16.41 | 2022 | |
| Xeris Pharmaceuticals, INC. | $15.98 | 2023 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.84 | 2023 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $14.16 | 2021 | |
| Alkermes, INC. | $12.69 | 2022 | |
| Dexcom, INC. | $11.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.